Cargando…

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple myeloma (MM). CD38−directed antibodies have several mechanisms of action. Fc−dependent immune effector mechanisms include complement-dependent cytotoxicity (CDC), antibody−dependent cell−mediated cytotoxicity (ADCC),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franssen, Laurens E., Stege, Claudia A. M., Zweegman, Sonja, van de Donk, Niels W. C. J., Nijhof, Inger S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230744/ https://www.ncbi.nlm.nih.gov/pubmed/32331242 http://dx.doi.org/10.3390/jcm9041195

Ejemplares similares

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Smits, F., et al.
Publicado: (2023)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
por: Mian, Hira, et al.
Publicado: (2020)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6p3mre68qbgb3bdlspd2fe4b3a